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In this study, we aimed to investigate the performance of nontreponemal antibody tests in cerebrospinal fluid (CSF) speci-
mens from syphilis patients. From September 2009 to September 2012, CSF specimens were collected at the Shanghai Skin
Disease Hospital in Shanghai, China, from 1,132 syphilis patients without HIV infection, including 154 with symptomatic
and 56 with asymptomatic neurosyphilis. All of the CSF specimens underwent testing with a rapid plasma reagin (RPR)
test, an RPR-V (commercial RPR antigen diluted 1:2 in 10% saline) test, the toluidine red unheated serum test (TRUST),
and the Venereal Disease Research Laboratory (VDRL) test. Specificities, sensitivities, positive predictive values (PPVs),
negative predictive values (NPVs), and kappa values were calculated to determine the performances of the tests. We com-
pared results of the CSF-VDRL, CSF-RPR, CSF-RPR-V, and CSF-TRUST among patients with symptomatic and asymptom-
atic neurosyphilis who had reactive CSF-Treponema pallidum particle agglutination (TPPA) test results. Overall, the CSF-
VDRL test was reactive in 261 patients (23.1%). There were no cases in which the CSF-VDRL was nonreactive and CSF-RPR,
CSF-RPR-V, or CSF-TRUST was reactive. Agreement between the results of CSF-TRUST and CSF-RPR was almost perfect ( 
0.861), with substantial agreement between the results of CSF-RPR and CSF-RPR-V (  0.740). The sensitivities of CSF-VDRL,
CSF-RPR, CSF-RPR-V, and CSF-TRUST were 81.4%, 76.2%, 79.5%, and 76.2%, respectively. Compared to CSF-VDRL, CSF-
RPR, CSF-RPR-V, and CSF-TRUST had comparable PPVs and NPVs. However, the specificity of CSF-VDRL (90.3%) was signifi-
cantly lower than those of the other tests (92.7 to 93.4%). Therefore, CSF-RPR, CSF-RPR-V, and CSF-TRUST can be considered
alternative tests for neurosyphilis diagnosis in HIV-negative populations, particularly when the CSF-VDRL is not
available.
Treponema pallidum subsp. pallidum, the pathogen of syphi-lis, can disseminate into the central nervous system (CNS)
within days after exposure (1). Neuroinvasion with T. pallidum
subsp. pallidum can lead to asymptomatic meningitis in approxi-
mately 14% to 20% of cases and, if untreated, can progress to
severe and irreversible symptomatic neurosyphilis with cerebro-
spinal fluid (CSF) abnormalities (2). Early diagnosis of neu-
rosyphilis is critical for timely treatment and minimization of se-
quelae.
The CSF-Venereal Disease Research Laboratory test (VDRL) is
currently considered the standard test for confirming a neu-
rosyphilis diagnosis (3, 4). However, several limitations have been
noted with the test, including its moderate sensitivity, lack of com-
mercial availability in resource-limited countries, and cumber-
some and time-consuming procedures.
Compared to VDRL, the rapid plasma reagin test (RPR) and
the toluidine red unheated serum test (TRUST) have similar test
principles and performance using serum specimens, are easier to
perform, and are available as commercial test kits (5, 6). RPR and
TRUST may be promising alternatives to VDRL when testing CSF
for neurosyphilis; however, their use in routine clinical practice is
currently controversial because of limited experience and pub-
lished reports in the literature. Therefore, we conducted this study
in order to compare the performance of CSF-VDRL, CSF-RPR,
and CSF-TRUST for the diagnosis of neurosyphilis, using a large
sample of patients identified with syphilis in China.
MATERIALS AND METHODS
Study participants. Between September 2009 and September 2012, we
recruited eligible patients diagnosed with syphilis prior to therapy who
presented to the Sexually Transmitted Disease Institute at the Shanghai
Skin Disease Hospital in Shanghai, China. The inclusion criteria for po-
tential subjects included age 18 years old, new syphilis diagnosis regard-
less of clinical stage (primary, secondary, or latent syphilis or suspected
neurosyphilis), or serofast status, which was defined as having a 4-fold
decline in titer after therapy and having a constant low RPR titer of 1:8
despite receiving standard syphilis treatment and having at least 2 years of
follow-up evaluation (7). In China, the standard treatment for early or late
syphilis (without neurosyphilis) consists of benzathine penicillin 2.4 MU
administered as intramuscular injections every week for 3 weeks. We ex-
cluded syphilis patients if they were less than 18 years old, pregnant, or
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coinfected with HIV and if they refused lumbar puncture for evaluation as
part of the study procedure. After obtaining written informed consent, we
interviewed each participant for a detailed medical history and performed
a routine neurologic examination for assessment of cranial nerve func-
tion, motor function, sensation, coordination, reflexes, and gait. Venous
blood and CSF were collected from all subjects for syphilis testing and
evaluation per standard clinic practice at the hospital in Shanghai. All the
participants also underwent HIV antibody testing. This study was ap-
proved by the ethics committee of the Shanghai Skin Disease Hospital.
Laboratory tests. For syphilis diagnosis, the serum RPR was per-
formed as the screening test, followed by the T. pallidum subsp. pallidum
particle agglutination test (TPPA) for confirmation (7). Routine testing of
CSF was conducted to examine the inflammatory responses in the CNS,
including the CSF white blood cell (WBC) count, red blood cell (RBC)
count, and total protein. The CSF samples underwent testing with CSF-
VDRL, CSF-RPR, and CSF-TRUST for neurosyphilis diagnosis, using the
same procedures applied to serum specimens. Furthermore, we diluted
commercial RPR antigen 1:2 in 10% saline, allowed it to stand for 5 min
before use, and named it CSF-RPR-V as described in a previous study (8).
All the tests described above were conducted using the same thawed CSF
aliquot from each participant on the same day by the same operator, who
was masked to the patient’s clinical status. All the laboratory tests were
performed in the central laboratory of the Shanghai Skin Disease Hospital
according to the standard methods.
Since we were comparing the test performance of the CSF-VDRL with
CSF-RPR, CSF-RPR-V, and CSF-TRUST, we were not able to use the
CSF-VDRL as the reference standard for neurosyphilis diagnosis. Rather,
we used CSF-TPPA as a marker in the diagnosis of neurosyphilis (9, 10,
11), which was internally validated as a CSF treponemal antibody-based
assay in our laboratory using CSF-fluorescent treponemal antibody ab-
sorption test (FTA-ABS) for comparison (unpublished data). The test
performance of CSF-TPPA is statistically equivalent to that of CSF-FTA-
ABS for neurosyphilis diagnosis (  0.953, P  0.001) (see the supple-
mental material).
Case definitions. The diagnosis and clinical stage of syphilis were de-
termined based on updated sexually transmitted disease surveillance case
definitions (12). Symptomatic neurosyphilis was defined as the combina-
tion of clinical symptoms or signs consistent with neurosyphilis without
other known causes of the clinical abnormalities, with a positive CSF-
TPPA in the absence of contamination with blood. Asymptomatic neu-
rosyphilis was defined as the combination of elevated CSF WBC count
(10/l) without other known causes, with a positive CSF-TPPA in the
absence of contamination with blood. Participants who had only a posi-
tive CSF-TPPA result in the absence of symptoms or CSF pleocytosis were
not considered to have neurosyphilis.
Statistical analysis. The Statistical Package for the Social Sciences for
Windows (SPSS, version 13.0; Chicago, IL) was used for statistical analy-
sis. Descriptive statistics were used to calculate the median and interquar-
tile range (IQR). Sensitivities, specificities, positive predictive values
(PPVs), negative predictive values (NPVs), and kappa values () were
calculated using standard formulae. The agreement of the results by 
value was categorized as almost perfect (0.81 to 1.0), substantial (0.61 to
0.80), moderate (0.41 to 0.60), fair (0.21 to 0.40), and slight (0.00 to 0.20).
Additionally, the chi-square test was performed to compare the propor-
tion between groups. Differences were considered to be statistically sig-
nificant at two-sided P values of 0.05.
RESULTS
Participant characteristics. A total of 1,132 eligible participants
were enrolled in the study prior to therapy with either primary,
secondary, or latent syphilis, suspected neurosyphilis, or serofast
status (Fig. 1). Among them, 154 and 56 participants were diag-
nosed with symptomatic neurosyphilis and asymptomatic neu-
rosyphilis, respectively, using the definitions above; four partici-
pants with neurologic symptoms and signs but negative results of
the CSF-TPPA were excluded from the analyses. The detailed
characteristics of the study participants are shown in Table 1 and
Table 2.
CSF-VDRL, CSF-RPR, CSF-RPR-V, and CSF-TRUST results.
The CSF-VDRL was reactive in 261 patients, among which the
number of samples that were also reactive by CSF-RPR, CSF-
RPR-V, and CSF-TRUST were 217, 225, and 220, respectively.
Among the 261 specimens with positive CSF-VDRL results, the
CSF-RPR, CSF-RPR-V and CSF-TRUST results were negative
among 16.9%, 13.8%, and 15.3%, respectively. There were no
specimens for which the CSF-VDRL was nonreactive but CSF-
FIG 1 Flow diagram of participant enrollment.


















Male (no. [%]) 627 (55.4) 85 (88.5) 174 (49.2) 151 (48.2) 77 (36.5) 140 (88.6)
Age (median [IQR]) (yr) 42 (30–54) 40.5 (32–53) 37 (28–52) 42 (30–57) 36 (29–50) 54 (46–58)
1/serum RPR titer (median [IQR]) 32 (8–64) 16 (4–32) 64 (32–128) 32 (4–64) 8 (4–16) 32 (16–64)
No. (%) CSF TPPA positive 409 (36.1) 0 (0.0) 80 (22.6) 99 (31.6) 76 (36.0) 154 (97.5)
No. (%) CSF WBCs 10/l 126 (11.1) 1 (1.0) 38 (10.7) 35 (11.2) 9 (4.3) 43 (27.2)
a IQR, interquartile range; RPR, rapid plasma reagin; CSF, cerebrospinal fluid; TPPA, Treponema pallidum particle agglutination; WBCs, white blood cells.
b Based on the presence of clinical symptoms or signs consistent with neurosyphilis without other known causes of the clinical abnormalities.
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RPR, CSF-RPR-V, or CSF-TRUST was reactive. Three samples
were reactive by CSF-RPR but nonreactive by CSF-TRUST, and
seven samples were reactive by CSF-TRUST but nonreactive by
CSF-RPR. Among the 208 samples that were reactive in all four
tests, the median serum RPR titers (1:4) and IQRs (1:2 to 1:8) were
statistically identical.
Among patients with symptomatic neurosyphilis, the  values
between the CSF-VDRL and the other CSF nontreponemal tests
were all substantial, at 0.709. Among the patients with asymptom-
atic neurosyphilis, the  values were 0.692 between CSF-VDRL
and CSF-RPR or CSF-TRUST and 0.781 between the CSF-VDRL
and CSF-RPR-V. Among patients with positive CSF-VDRL re-
sults, the agreement between the results of CSF-TRUST and CSF-
RPR was almost perfect (  0.861), and there was substantial
agreement between the results of CSF-RPR and CSF-RPR-V ( 
0.740) (Table 3).
Table 4 shows the overall sensitivities, specificities, PPVs, and
NPVs of the four CSF nontreponemal tests among participants
based on our definitions of neurosyphilis. CSF-VDRL and CSF-
RPR-V had the highest sensitivities; however, there were no sta-
tistical differences in sensitivities among the four tests. The spec-
ificity of CSF-VDRL was significantly lower than that of CSF-RPR
(90.3% versus 93.4%, P  0.017) and CSF-TRUST (90.3% versus
93.1%, P  0.028). The PPVs and NPVs of those four tests were
not statistically different (P  0.05).
When we distinguished between symptomatic and asymptom-
atic neurosyphilis, we found that the four CSF nontreponemal
tests had better test performances for diagnosing symptomatic
neurosyphilis than did asymptomatic neurosyphilis (Table 5). For
diagnoses of symptomatic neurosyphilis, the sensitivities, PPVs,
and NPVs of the four tests were virtually identical; however, the
specificity of the CSF-VDRL was significantly lower than that of
CSF-RPR (86.7% versus 90.2%, P  0.019) and the CSF-TRUST
(86.7% versus 90.1%, P  0.023). For diagnosing asymptomatic
neurosyphilis, we found no statistical differences in the sensitivi-
ties, specificities, PPVs, and NPVs of the four tests.
We also compared the characteristics of the participants with
inconsistent CSF-VDRL, CSF-RPR, CSF-RPR-V, or CSF-TRUST
results. The CSF WBC count was statistically higher among pa-
tients who were CSF-VDRL positive (CSF-VDRL)/CSF-RPR
and CSF-VDRL/CSF-TRUST than those with inconsistent re-
sults. The CSF protein was also statistically higher among patients
who were CSF-VDRL/CSF-RPR, CSF-VDRL/CSF-RPR-V,
and CSF-VDRL/CSF-TRUST than those with inconsistent re-
sults (Table 6). However, these differences may not be meaningful
from a clinical standpoint.
DISCUSSION
The CSF-VDRL has a high specificity and is currently considered
the definitive test for diagnosis of neurosyphilis globally. How-
ever, the reagent needs to be prepared and must be used within 2 h,
and a light microscope is required for detection (13). Therefore,
there is a need to identify simpler, more convenient and more
efficient methods as alternative CSF assays. We analyzed data
from the largest study to date involving 210 neurosyphilis patients
and found that for diagnosis of neurosyphilis based on our defi-
nitions, CSF-RPR, CSF-RPR-V, and CSF-TRUST had comparable
sensitivities (76.2 to 79.5%) and higher specificities (92.7 to
93.4%) than the CSF-VDRL (sensitivity 81.4%, specificity 90.3%).
Our findings are consistent with the reports from Castro et al.
(5) regarding the performance of CSF-RPR and Jiang et al. regard-
ing the CSF-TRUST, which involved 24 and 41 neurosyphilis pa-
tients, respectively (6). In an earlier study in 1985, Larsen et al.
concluded that CSF-RPR and CSF-TRUST had statistically signif-
icantly lower sensitivities and specificities than CSF-VDRL; how-
TABLE 2 Characteristics of the participants diagnosed with











Male (no. [%]) 176 (83.8) 39 (69.6) 137 (89.0)
Age (median [IQR]) (yr) 54 (45–59) 52 (37–61) 54 (47–58)
1/serum RPR titer (median [IQR]) 32 (16–64) 64 (32–128) 32 (16–64)
No. (%) CSF-TPPA positive 210 (100.0) 56 (100.0) 154 (100.0)
No. (%) CSF WBCs 10/l 99 (47.1) 56 (100.0) 43 (27.9)
a IQR, interquartile range; RPR, rapid plasma reagin; CSF, cerebrospinal fluid; TPPA,
Treponema palladium particle agglutination; WBCs, white blood cells.
b Based on the combination of elevated CSF WBCs count (10/l) without other
known causes and a positive CSF-TPPA in the absence of contamination with blood.
c Based on the combination of clinical symptoms or signs consistent with neurosyphilis
without other known causes of the clinical abnormalities, and a positive CSF-TPPA in
the absence of contamination with blood.
TABLE 3 Comparisons between CSF-RPR and CSF-RPR-V or CSF-TRUST results among 261 participants with positive results of the CSF-VDRL
CSF-RPR
results
CSF-RPR-V results CSF-TRUST results
 (no.)  (no.) P  (P)  (no.)  (no.) P  (P)
 (no.) 212 5 0.096 0.740 (0.001) 213 3 0.344 0.861 (0.001)
 (no.) 13 31 7 37
RPR, rapid plasma reagin; RPR-V, RPR antigen diluted 1:2 in 10% saline and used as in the CSF-VDRL; TRUST, toluidine red unheated serum test.
TABLE 4 Sensitivities, specificities, positive predictive values, and






(95% CI) PPVd (95% CI) NPVe (95% CI)
VDRL 81.4 (75.4–87.4) 90.3 (88.3–92.3) 65.8 (61.8–71.8) 95.5 (94.5–96.5)
RPR 76.2 (70.2–82.2) 93.4 (91.4–95.4) 72.4 (66.4–78.6) 94.5 (93.5–95.5)
RPR-V 79.5 (73.5–85.5) 92.7 (90.7–94.7) 71.4 (65.4–77.4) 95.2 (94.2–96.2)
TRUST 76.2 (70.2–82.2) 93.1 (91.1–95.1) 71.7 (65.8–77.8) 94.5 (92.5–96.5)
a Neurosyphilis was defined as the combination of elevated CSF WBCs count (10/l)
without other known causes, or clinical symptoms or signs consistent with
neurosyphilis without other known causes of the clinical abnormalities, and a positive
CSF-TPPA in the absence of contamination with blood.
b VDRL, venereal disease research laboratory test; RPR, rapid plasma reagin test; RPR-
V, RPR antigen diluted 1:2 in 10% saline and used as in the CSF-VDRL; TRUST,
toluidine red unheated serum test.
c CI, confidence interval.
d PPV, positive predictive value.
e NPV, negative predictive value.
Zhu et al.
738 jcm.asm.org Journal of Clinical Microbiology
ever, their study was limited by a small sample of patients and
older diagnostic techniques (14).
A more recent study involving 72 patients with neurosyphilis,
Marra et al. reported that CSF-RPR and CSF-RPR-V had lower
sensitivities of 51.5% and 57.6%, respectively, compared to 66.7%
for the CSF-VDRL for symptomatic neurosyphilis (8). They also
stated that CSF-RPR had a high false-negative rate of 35.6%;
therefore, CSF-RPR was not recommended as an alternative for
CSF-VDRL. However, we found that the false-negative values of
CSF-RPR, CSF-RPR-V, and CSF-TRUST were 16.9%, 13.8%, and
15.3%, respectively, compared to the CSF-VDRL. The differences
in these findings may be due to the HIV status of the study popu-
lations and the definitions for neurosyphilis. In the study by Marra
et al., most of the syphilis patients were coinfected with HIV, and
in these patients the investigators defined a CSF WBC count of
20/l as one of the diagnostic criteria for neurosyphilis (8). In
comparison, all of our study participants were HIV negative and
we used a CSF WBC count of 10/l according to the updated
CDC guidelines in China (7). Another study comparing the CSF-
TRUST and CSF-VDRL among an HIV-negative population with
neurosyphilis was conducted by Gu et al. (15). However, they did
not provide clinical data, making it difficult to differentiate syph-
ilis patients who had received therapy from those who received
initial treatment and to make further comparisons with our study.
We found that CSF-RPR-V had better agreement (  0.781)
with the CSF-VDRL than CSF-RPR (  0.692). CSF-RPR-V also
resulted in a slightly higher sensitivity for neurosyphilis diagnosis
than CSF-RPR and CSF-TRUST, although these results were not
statistically significant. Therefore, if CSF-VDRL is not available
and there are resources to conduct the additional steps to dilute
RPR antigen 1:2 in 10% saline, CSF-RPR-V should be considered
an alternative test for neurosyphilis diagnosis.
Some limitations of this study should be acknowledged. First, it
is generally known that evaluation of diagnostic tests varies based
on definitions of the gold standard. There is actually no diagnostic
gold standard for neurosyphilis, although the CSF-VDRL has
been widely used in clinical practice. Since we aimed to compare
the diagnostic performance of CSF-VDRL with CSF-RPR, CSF
RPR-V, and CSF-TRUST, we could not use CSF-VDRL as a refer-
ence standard. Rather, as a marker to assist in our definitions of
symptomatic and asymptomatic neurosyphilis, we used the CSF-
TPPA, which is recommended as one of the diagnostic tests for
neurosyphilis in the European guidelines (9). In our study, we
found no cases in which the CSF-VDRL was reactive but the CSF-
TPPA was nonreactive, supporting the feasibility of using the CSF-
TPPA since no confirmed neurosyphilis cases were missed. Sec-
ond, we did not include syphilis patients coinfected with HIV,
since they may have impaired antibody responses to the antigen
used in VDRL, RPR, and TRUST on CSF. Any generalization of
the results from this study to HIV-positive or other immunocom-
promised patients should therefore be made with caution. Lastly,
we found no statistical difference in sensitivities between the four
CSF nontreponemal tests, which may have been due to our sample
size of participants with neurosyphilis. Although we analyzed data
from the largest study to date, involving 210 neurosyphilis pa-
tients, this number may still not have been sufficient to detect
significant differences in sensitivities between the tests.
Syphilis is now resurgent with a vengeance in China, the largest
TABLE 5 Sensitivities, specificities, positive predictive values, and negative predict values of the four CSF nontreponemal tests for symptomatic and
asymptomatic neurosyphilis diagnosis
Testa








(95% CI) PPV (95% CI) NPV (95% CI)
VDRL 85.7 (79.7–91.7) 86.7 (84.7–88.7) 50.8 (44.8–56.8) 97.5 (96.5–98.5) 69.6 (59.6–79.6) 79.4 (77.4–81.4) 15.0 (11.0–19.0) 98.0 (97.2–98.8)
RPR 81.8 (75.8–87.8) 90.2 (88.2–92.2) 57.0 (51.0–63.0) 96.9 (95.9–97.9) 60.7 (50.7–70.7) 82.6 (80.6–84.6) 15.4 (11.4–19.4) 97.6 (96.6–98.6)
RPR-V 83.1 (77.1–89.1) 89.1 (87.1–91.1) 54.7 (48.7–60.7) 97.1 (96.1–98.1) 69.6 (59.6–79.6) 81.8 (79.8–83.8) 16.7 (12.7–20.7) 98.1 (97.1–99.1)
TRUST 82.5 (76.5–88.5) 90.1 (88.1–92.1) 57.0 (53.0–63.0) 97.0 (96.0–98.0) 58.9 (48.9–68.9) 82.1 (80.1–84.1) 14.8 (10.8–18.8) 97.5 (96.5–98.5)
a VDRL, venereal disease research laboratory test; RPR, rapid plasma reagin test; RPR-V, RPR antigen diluted 1:2 in 10% saline and used as in the CSF-VDRL; TRUST, toluidine red
unheated serum test.
b Based on the combination of clinical signs or symptoms consistent with neurosyphilis without other known causes of the clinical abnormalities, and a positive CSF-TPPA in the
absence of contamination with blood. PPV, positive predictive value; NPV, negative predictive value.
c Based on the combination of elevated CSF WBCs count (10/l) without other known causes, and a positive CSF-TPPA in the absence of contamination with blood.
TABLE 6 Comparison of the characteristics of the participants with inconsistent results between CSF-VDRL and the CSF-RPR, CSF-RPR-V, or
CSF-TRUST
Participant characteristic













Male (no. [%]) 163 (75.1) 30 (68.2) 0.341 167 (74.2) 26 (72.2) 0.801 159 (74.6) 31 (67.4) 0.315
Age (median [IQRb]) (yr) 53 (45–60) 49 (32–59) 0.034 53 (45–60) 49 (33–58) 0.090 53 (45–60) 49 (33–59) 0.030
CSF WBCs/lc (median [IQR]) 5.0 (2.0–18.8) 2.6 (1.0–8.6) 0.014 4.4 (2.0–16.8) 2.0 (0.3–7.9) 0.207 4.4 (2.0–19.3) 3.3 (1.0–7.3) 0.001
CSF protein (median [IQR]) (mg/dl) 0.5 (0.3–0.6) 0.3 (0.2–0.4) 0.001 0.5 (0.3–0.6) 0.3 (0.2–0.5) 0.014 0.5 (0.3–0.7) 0.3 (0.2–0.5) 0.001
1/serum RPR titer (median [IQR]) 64 (32–128) 32 (16–64) 0.681 64 (32–128) 32 (16–64) 0.890 64 (32–128) 32 (16–64) 0.079
a VDRL, venereal disease research laboratory; RPR, rapid plasma reagin; RPR-V, RPR antigen diluted 1:2 in 10% saline and used as in the CSF-VDRL; TRUST, toluidine red
unheated serum test.
b IQR, interquartile range.
c WBCs, white blood cells.
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developing country globally (16), and the incidence of neurosyph-
ilis may increase accordingly. Since the CSF-VDRL is not widely
available in all hospitals, because of the limitations mentioned
above, this precludes the early diagnosis and timely treatment of
neurosyphilis. We found that CSF-RPR, CSF RPR-V, and CSF-
TRUST (which are attractive since the commercial test kits for
TRUST and RPR are widely used in China) have sensitivities,
specificities, PPVs, and NPVs comparable to those of the CSF-
VDRL. Furthermore, conducting CSF-RPR or CSF-TRUST is less
expensive than conducting the CSF-VDRL (15 yuan per test ver-
sus 90 yuan per test). Therefore, we recommend that CSF-RPR,
CSF RPR-V, or CSF-TRUST be considered as alternative tests for
neurosyphilis diagnosis in HIV-negative populations. These alter-
native CSF nontreponemal tests will result in false-negative rates
that range between 14 and 17%, but are preferable to having no
test at all for neurosyphilis diagnosis in areas where the CSF-
VDRL is not available.
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